



List of insider information under Art. 7 of Regulation (EU) 596/2014 of the European Parliament and of the Council of 16 April 2014 regarding market abuse (Regulation on market abuse) on the circumstances that occurred in the first quarter of 2024

02 January 2024

Notification from Ognian Donev under Art. 19 of Regulation (EU) № 596/2014 of the European Parliament and of the Council of April 16, 2014 from 22 December 2023

Date	Operation	Number of shares	Price (BGN)
22.12.2023	Buy	21 000	5,71

10 January 2024

Notification regarding terms and conditions for payment of dividend

Sofia, Bulgaria, January 10, 2024 – In accordance with the requirements of art. 100 of LPOS “Sopharma” AD (SFA: Bulgarian Stock Exchange, SPH: Warsaw Stock Exchange) notifies that on January 22, 2024 the Company will initiate the payment of the dividend for the 6 months of 2023 of 90 stotinki voted on the Extraordinary General Meeting of Shareholders held on November 24, 2023. The shareholders eligible for dividend are those registered in the book of shareholders 14 days after the date of the EGM on which the distribution of dividend was voted, i.e. December 08, 2023. In accordance with the Regulations of the Central Depository, the dividend shall be paid out as follows: for shareholders with client accounts at an investment intermediary – through the respective investment intermediary, for shareholders with personal accounts at the “Central Depository” AD - through the branches of “Eurobank Bulgaria” AD /Postbank/ in the country.

15 January 2024

Notification merger of the subsidiary "Veta pharma" AD into “Sopharma” AD

Sofia, Bulgaria, 15 January 2024 – According to the requirements of art. 100t of LPOS, “Sopharma” AD (SFA: “BSE” AD, SPH: Warsaw Stock Exchange) notifies that the Board of Directors of "Sopharma" AD adopted a decision to initiate a procedure for the merger of the subsidiary "Veta pharma" AD, UIC: 104111084 in "Sopharma" AD under the conditions and in accordance with Chapter XVI of the Commercial Law and Art. 122 of the Law on the Public Offering of Securities. At the start of the procedure Sopharma AD owns 99.98% in the capital of the company.

19 January 2024

Presentation of materials for the convening of the General Meeting of the holders of warrants of "Sopharma" AD

The Board of Directors hereby convenes a General Meeting of the holders of warrants of “SOPHARMA” AD with the unique identification code SFAGMW26012024 to be held on 26 January 2024 at 11:00 a.m. (9:00 UTC) at the Company's headquarters in Sofia city with place of holding: 5 Lachezar Stanchev Str., Ground Floor, Sopharma Business Towers, Sopharma Event Center, and in the absence of a quorum on that date - on 26 January 2024 at the same location, with the same starting time and agenda.

Pursuant to Article 16a, para. 2 of the Articles of Association of the Company and Article 115b, para. 5 of the LPOS, the Board of Directors hereby notifies the Warrant holders that at the General Meeting of Warrant holders scheduled to be held on 26 January 2024 and, in the absence of a quorum on that date, on 5 February 2024, voting by correspondence and electronic means will be accepted as per the rules described in this notice.






That the General Meeting of Warrant holders scheduled to be held on 26 January 2024 be held with the following agenda and with the following proposed resolutions by the Board of Directors:
Substantive issues:

1. Adoption of a Report on the movement of the price of ordinary shares of "SOPHARMA" AD on the regulated market, organized by the "Bulgarian Stock Exchange" AD, for the last 12 months; Draft decision: The General meeting of warrant holders adopts a Report on the movement of the price of ordinary shares of "SOPHARMA" AD on the regulated market, organized by the "Bulgarian Stock Exchange" AD, for the last 12 months;

2. Adopting a decision to exercise the warrants' rights. Draft decision: The General meeting of the warrant holders with ISIN BG9200001212 adopts a decision to exercise the rights to subscribe shares from a future increase in the capital of "SOPHARMA" AD, by issuing 7 133 264 number of ordinary, registered, dematerialized shares, with the right to vote, with a nominal value of BGN 1 each and an issue value of BGN 4.13 per share, provided that the shares from the increase are subscribed solely by the warrant holders;

3. Requesting that the Board of Directors adopts a decision on a conditional capital increase. Draft decision: Requesting that the Board of Directors adopts a decision on a capital increase under the provisions of the Company's Articles of Association, Art. 195 of the Commercial Code and in accordance with art. 113, para. 2, item 2 of the LPOS, in which the warrant holders can exercise their rights under item 2 of the agenda, and under the terms and conditions described in the Prospectus for the public offering of warrants, confirmed with a Decision of the Financial Supervision Commission № 804 – E/04.11.2021.

Attachments:

-  [Information on the share price of Sopharma AD for the past 12 months](#)
-  [Sample of declaration for voting through correspondence](#)
-  [Sample proxy](#)
-  [Invitation for General Meeting of Warrant holders of Sopharma AD](#)
-  [Minutes of meeting of the Board of directors of Sopharma AD](#)

22 January 2024

Sales revenues for December 2023

Sofia, Bulgaria, January 22, 2024 – According to the requirements of art. 100t of LPOS, "Sopharma" AD (SFA: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) notifies that for December 2023 the Company recorded a decrease in sales of 57% compared to the same month of the previous year, incl. 27% decrease in domestic sales and 68% decrease in export sales.

For 2023 the revenues from sales of products increase by 7%, incl. 1% increase of sales for the domestic market and 11% increase in export sales.

26 January 2024

Notification according to Art. 89t of the LPOS concerning an increase of the capital of "Sopharma" AD

Sofia, Bulgaria 26 January 2024 - According to the requirements of Art. 89t of the LPOS, "Sopharma" AD (SFA: Bulgarian Stock Exchange, SPH: Warsaw Stock Exchange) notifies all

interested parties that the Company (on the basis of Art. 89t of the Law on the Public Offering of Securities, in connection with the decision of the General Meeting of Warrant Holders (GMWH) dated 26.01.2024 and decision of the Board of Directors of "SOPHARMA" AD dated 26.01.2024 and on the basis of Art. 195 and 196 of the Commercial Law (CL), Art. 113, para. 2, it. 2 of the LPOS and Art. 25 of the Company's Articles of Association) has launched a capital increase procedure by issuing up to 7 133 264 ordinary registered, dematerialized, freely transferable shares, provided that the shares from the increase are subscribed by the holders of warrants from issue ISIN BG9200001212, in accordance with the terms and conditions described in the Prospectus for the public offering of warrants, confirmed with Decision of the Financial Supervision Commission No. 804-E/04.11.2021.

The capital of "SOPHARMA" AD will be increase on the basis of Art. 195 of the Commercial Code by exercising the rights of the holders of warrants with ISIN BG9200001212, by subscribing shares from a future capital increase of up to 7 133 246 ordinary, registered, dematerialized shares, with one voting right, with a nominal value of BGN 1 each and an issue value of BGN 4.13 per share, provided that the shares from the increase are subscribed only by the warrant holders. The capital increase will be carried out by exercising up to 7 133 246 dematerialized, freely transferable unexercised warrants from an issue with ISIN BG9200001212, upon explicit intent to exercise by the warrant holders.

The Board of Directors of "SOPHARMA" AD has designated "SOFIA INTERNATIONAL SECURITIES" AD, EIK: 121727057, with registered office and management address: Sofia, Sredets district, 140 Georgi S. Rakovski Str., 4th floor, for an investment intermediary to service the capital increase of "SOPHARMA" AD and the subscription of shares that will be issued by the Company against the exercise of the issue of warrants with ISIN BG9200001212.

30 January 2024

Individual financial report according to IFRS as of 31 December 2023

Attachments:


-  [Additional information as of 31 December 2023](#)
-  [Management report as of 31 December 2023](#)
-  [Insider information as of 31 December 2023](#)
-  [Information according to Annex 4 of Ordinance 2 as of 31 December 2023](#)
-  [Individual financial report according to IFRS as of 31 December 2023](#)
-  [Notes to the individual financial report as of 31 December 2023](#)
-  [Individual financial report according to BFSC standards as of 31 December 2023](#)
-  [Declaration by the responsible directors as of 31 December 2023](#)
-  [Individual financial report according to IFRS as of 31 December 2023- Excel](#)

31 January 2024

Notification regarding technical error in the Notification under Art. 89t of the Law on

Due to an obvious technical error in the Notification under Art. 89t of the Law on Public Offering of Securities concerning the increase of the capital of "SOPHARMA" AD, EIK 831902088, with registered office and management address Sofia, Nadezhda district, 16, Iliensko shose street by exercising warrants from an issue with ISIN code BG9200001212 published on 26 January 2024, please read "7 133 246" as "7 133 264" everywhere in the text of the notification. blic Offering of Securities published on 26.01.2024

Attachments:

-  [Technical error in the Notification under Art. 89t of the Law on Public Offering of Securities published on 26.01.2024](#)

19 February 2024

Sales revenues for January 2024

Sofia, Bulgaria, February 19, 2024 – According to the requirements of art. 100t of LPOS, “Sopharma” AD (SFA: “Bulgarian Stock Exchange” AD, SPH: Warsaw Stock Exchange) notifies that for January 2024 the Company recorded an increase in sales of 32% compared to the same month of the previous year, incl. 16% increase in domestic sales and 44% increase in export sales.

Attachments:

 [Sales revenues for January 2024](#)

20 February 2024

Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 as of 20 February 2024 re exercising warrants

Date	Operation	Number of warrants	Price (BGN)
19.02.2024	exercising warrants	1 667 000	

20 February 2024

Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 as of 20 February 2024 re subscribing shares

Date	Operation	Number of shares	Price (BGN)
19.02.2024	Buy	1 667 000	4,13

22 February 2024

Notification from "Donev Investments Holding" AD under Art. 19 of Regulation (EU) No. 596/2014 of 19 February 2024 on the exercise of warrants in a capital increase under the condition

Date	Operation	Number of warrants	Price (BGN)
19.02.2024	Buy	4 328 000	

22 February 2024

Notification from "Donev Investments Holding" AD under Art. 19 of Regulation (EU) No. 596/2014 of 19 February 2024 on the acquisition of shares from a temporary issue/exercise of warrants

Date	Operation	Number of shares	Price (BGN)
19.02.2024	Buy	4 328 000	4,13


27 February 2024

Results of conditional capital increase of Sopharma AD by exercising warrants

Sofia, Bulgaria, February 27, 2024 – According to the requirements of art. 100t of LPOS, “Sopharma” AD (SFA: Bulgarian Stock Exchange, SPH: Warsaw Stock Exchange) notifies that in pursuance of a decision of the General meeting of Holders of Warrants (GMHW) held on January 26, 2024 and decision of the Board of Directors of SOPHARMA AD from a meeting held on January 26, 2024 and based on art. 195 and art. 196 of the Commercial Law (CL), art. 113, para. 2, item 2 of Law on public offering of securities (LPOS) and art. 25 of the Articles of incorporation of the company a procedure for capital increase was launched for issuing up to 7 133 264 ordinary registered dematerialized freely transferable shares with a nominal value of BGN 1 each and issue value of BGN 4.13 for one share, under the condition that the shares of the increase are subscribed by the holders of warrants of issue with ISIN BG9200001212, in accordance with the terms and conditions described in the Prospectus for Public Offering of Warrants, confirmed by a Decision of the Financial Supervision Commission (FSC) No 804-E / 04.11.2021.

The deadline for exercising warrants set by the Board of Directors in accordance with the requirements of the LPOS and the Prospectus for Public Offering of Warrants, confirmed by FSC Decision No 804-E / 04.11.2021 started on February 2, 2024 and ended on February 23, 2024. For this period, a total of 36 applications for subscription of the shares from the increase through the exercise of warrants were submitted by 36 applicants, including 3 legal entities and 33 individuals. A total of 6 510 985 (six million five hundred ten thousand nine hundred eighty five) warrants was exercised. 6 509 485 (six million five hundred and nine thousand four hundred and eighty-five) shares were registered against them - with 1 500 shares less - due to the fact that a request submitted by an individual has not been paid to the special bank account of "SOPHARMA" AD within the established period.





Attachments:





 [Results of conditional capital increase of Sopharma AD by exercising warrants from an issue with ISIN BG9200001212](#)

29 February 2024

„Sopharma” AD presented Consolidated quarterly financial report

Attachments:

-  [Individual financial report according to BFSC standards as of 31 December 2023](#)
-  [Information according to Annex 4 of Ordinance 2 as of 31 December 2023](#)
-  [Additional information as of 31 December 2023](#)
-  [Insider information as of 31 December 2023](#)

-  [Individual financial report according to IFRS as of 31 December 2023](#)
-  [Declaration by the responsible directors as of 31 December 2023](#)
-  [Notes to the individual financial report as of 31 December 2023](#)
-  [Management report as of 31 December 2023](#)

11 March 2024

Notification from "Donev Investments Holding" AD under Art. 19 of Regulation (EU) No. 596/2014 of 08 March 2024 on the acquisition of shares from a capital increase

Date	Operation	Number of shares	Price (BGN)
08.03.2024	"Certified account with shares from a capital increase subject to the exercise of warrants	4 328 000	

12 March 2024

Incoming transfer from capital increase subject to exercise of warrants

Date	Operation	Number of shares	Price (BGN)
11.03.2024	"Certified account with shares from a capital increase subject to the exercise of warrants	1 667 000	

20 March 2024

Sales revenues for February 2024

Sofia, Bulgaria, March 20, 2024 – According to the requirements of art. 100t of LPOS, "Sopharma" AD (SFA: "Bulgarian Stock Exchange" AD, SPH: Warsaw Stock Exchange) notifies that for February 2024 the Company recorded an decrease in sales of 29% compared to the same month of the previous year, incl. 9% decrease in domestic sales and 43% decrease in export sales. From the beginning of 2024, the Company recorded a decrease in sales of 3%, incl. 2% growth in domestic sales and 7% decrease in export sales.